54766-52-8

Upstream product

• 1027324-14-6 1-Bromo-4,4-diphenyl-butan-2-ol 
• 5409-60-9 4,4-diphenylbutan-2-one 
• 101-81-5 Diphenylmethane 
• 4286-85-5 4,4-diphenyl-1-butene 

Downstream Products

• 1025959-05-0 1-(2-Amino-2-methyl-propoxy)-4,4-diphenyl-butan-2-ol 
• 973-30-8 1-(4,4-diphenyl-2-hydroxybutyl)piperidinium chloride 
• 62373-45-9 N,N-di-n-propyl-4,4-diphenyl-2-hydroxybutylamine 
• 68162-52-7 N-isopropyl-4,4-diphenyl-2-hydroxybutylaminium chloride 
• 149553-41-3 tert-butyl N-<1,1-dimethyl-2-(2-methylsulfonyl-4,4-diphenylbutyloxy)ethyl>carbamate 
• 149553-40-2 tert-butyl N-<2-(2-hydroxy-4,4-diphenylbutyloxy)-1,1-dimethylethyl>carbamate 

Relevant academic research and scientific papers

Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model

In this study we have generated a pharmacophore model of triple uptake inhibitor compounds based on novel asymmetric pyran derivatives and the newly developed asymmetric furan derivatives. The model revealed features important for inhibitors to exhibit a

Agents for the treatment of overactive detrusor. IV. Synthesis and structure-activity relationships of cyclic analogues of terodiline

A series of pyrrolidine derivatives were synthesized and examined for inhibitory activity on detrusor contraction in vivo. Among those compounds, 5,5-dimethyl-2-(2,2-diphenylethyl)-3-isopropylidenepyrrolidine hydrochloride (41 · HCl), 2-(2,2-di(4-fluorophenyl)ethylene)-5,5-dimethyl-3-isopropylidenepyrrol idine hydrochloride (42 · HCl), (+)5,5-dimethyl-2-(N,N-diphenylaminomethyl)-3-isopropylidenepyrrolidin e hydrochloride (+)-(43a · HCl),(-)-5,5-dimethyl-2-(N,N-diphenylaminomethyl)-3-isopropylidenepyrr olidine hydrochloride (-)-(43a · HCl), and 2-(N,N-di(4-fluorophenyl)aminomethyl)-5,5-dimethyl-3-isopropylidenepyr rolidine methanesulfonate (43b · MsOH) showed stronger inhibitory activity on detrusor contraction than terodiline.